# Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

> **NCT02000622** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 302 (actual)

## Conditions studied

- Breast Cancer Metastatic
- BRCA 1 Gene Mutation
- BRCA 2 Gene Mutation

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Physician's choice chemotherapy

## Key facts

- **NCT ID:** NCT02000622
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-27
- **Primary completion:** 2016-12-09
- **Final completion:** 2025-12-23
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02000622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02000622, "Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02000622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*